Search - tctmd.com

Displaying 741 - 760 of 778

Sort: Relevancy | Date

News Daily News

Use of Evidence-Based Medical Therapy Steadily Improving in Acute MI Patients Postdischarge

Michael O'Riordan

September 30, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Daily News

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Michael O'Riordan

September 16, 2016

News Daily News

Intensive SPRINT Blood Pressure Reduction Would Prevent 100,000 Deaths per Year

Michael O'Riordan

September 15, 2016

News Daily News

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Michael O'Riordan

September 13, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

尽管有战乱和冲突，但缺血性心脏病的死亡率仍然迎来了“阿拉伯之春”

Michael O'Riordan

August 26, 2016

News Daily News

Despite War and Strife, Ischemic Heart Disease Leads Deaths in ‘Arab Spring’

Michael O'Riordan

August 26, 2016

News Daily News

A pesar de la Muerte y las Penurias, la Cardiopatía Isquémica es la Principal Causa de Muerte en la ‘Primavera Árabe’

Michael O'Riordan

August 26, 2016

News Daily News

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

Michael O'Riordan

August 18, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

FDA: Global Recall for Roadrunner UniGlide Wire Guides After Coating Contaminated

Michael O'Riordan

August 17, 2016

News Daily News

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

Michael O'Riordan

August 16, 2016

News Daily News

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Michael O'Riordan

August 12, 2016

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

Advertisement

Use of Evidence-Based Medical Therapy Steadily Improving in Acute MI Patients Postdischarge

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Intensive SPRINT Blood Pressure Reduction Would Prevent 100,000 Deaths per Year

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

尽管有战乱和冲突，但缺血性心脏病的死亡率仍然迎来了“阿拉伯之春”

Despite War and Strife, Ischemic Heart Disease Leads Deaths in ‘Arab Spring’

A pesar de la Muerte y las Penurias, la Cardiopatía Isquémica es la Principal Causa de Muerte en la ‘Primavera Árabe’

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

The Bioresorbable Stent Story So Far: What Promise? What Price?

FDA: Global Recall for Roadrunner UniGlide Wire Guides After Coating Contaminated

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content